A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs A002-MeiraGTx (Primary)
  • Indications Colour vision defects
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 13 Sep 2017 According to Applied Genetic Technologies Corporation media release, the company is currently conducting site initiation activities and screening patients for enrollment in this Phase 1/2.
    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 22 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top